TrialSignal
Clinical trial intelligence report
Denosumab In Ebv Related Nasopharyngeal Carcinoma (Npc) As A Model For Rank-Mediated Immunologic Modulation Of Virus-Related Tumours - Dern Study
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03923842
Status
UNKNOWN
Phase
PHASE2
Sponsor
Gruppo Oncologico del Nord-Ovest
Executive brief
Investment-Ready Snapshot
The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first line NPC recurrent/metastatic patients
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03923842
Indication
Nasopharyngeal Carcinoma
Modality
small molecule
Target
Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care
Intervention
Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.